Antiretroviral therapy (ART) effectively reduces cycles of viral replication but does not target
proviral populations in cells that persist for prolonged periods and that can undergo clonal …

Multiple cellular HIV reservoirs in diverse anatomical sites can undergo clonal expansion
and persist for years despite suppressive antiretroviral therapy, posing a major barrier …

Background HIV-1-associated immune activation drives CD4+ T cell depletion and the
development of acquired immunodeficiency syndrome. We aimed to determine the role of …

One strategy for a functional cure of HIV-1 is “block and lock”, which seeks to permanently
suppress the rebound of quiescent HIV-1 by epigenetic silencing. For the bivalent promoter …

Background Elite controllers are able to control viral replication without antiretroviral therapy.
Exceptional elite controllers do not show disease progression for more than 25 years …

Current antiretroviral therapy for HIV-1 infection does not represent a cure for infection as
viral rebound inevitably occurs following discontinuation of treatment. The “block and lock” …

Background: HIV persistence during antiretroviral therapy (ART) is the principal obstacle to
cure. Lymphoid tissue is a compartment for HIV, but mechanisms of persistence during ART …

HIV can establish a long-lived latent infection in cells harboring integrated non-expressing
proviruses. Latency reversing agents (LRAs), including protein kinase C (PKC) modulators …

People living with HIV (PLWH) despite having appreciable depletion of CD4+ T-cell show a
good SARS-CoV-2 vaccination response. The underlying mechanism (s) are currently not …

Despite effective antiretroviral therapies, chronic inflammation and spontaneous viral “blips”
occur in HIV-infected patients. Given the roles for monocytes/macrophages in HIV …